This CPB has been revised to state that: (i) TAVI by means of an FDA-approved aortic valve is considered medically necessary for persons with aortic valve stenosis who are determined to be at low-risk for death and complications with open-heart surgery; and (ii) transcatheter aortic valve implantation is considered experimental and investigational for bicuspid aortic stenosis, and porcelain aorta.